You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Preclinical Trial of Therapeutic Angiogenesis Plus Angioplasty and Stenting for Renal Vascular Disease

    SBC: LEFLORE TECHNOLOGIES LLC            Topic: 400

    Abstract Chronic kidney disease CKD is a progressive disorder affecting almost of the general population and this disease has shown a relentless growth over the past decades Patients with CKD have higher rates of hospitalization greater mortality shorter life expectancy and their healthcare costs are up to times more expensive than non CKD patients Thus treatments to slow halt ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Validation of a Diagnostic Test for Borrelia miyamotoi

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    ABSTRACT Borrelia miyamotoi is a tick transmitted spirochete recently shown to cause infection and disease in the United StatesEurope and AsiaA member of the relapsing fever group of Borreliathis pathogen has been proven to cause most commonly a nonspecificflu like illness with feverfatiguemyalgiaand headacheDisease can be particularly severe and involve the central nervous system in immunocomprom ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Targeting STT3A and STT3B to Block Flavivirus Replication

    SBC: New England Discovery Partners, LLC            Topic: NIAID

    AbstractMosquito borne flaviviruses cause disease worldwidewith members such as dengue virusDENVZika virusZIKVand west nile virusWNVinfecting more thanmillion individuals annuallyThe availability of small molecule antivirals that reduce flavivirus infection therefore could have an immediate and substantial impact on public health programs that seek to improve outcomes for populations infected with ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Turnkey THz Spectroscopy Polarimetry System for Pharmaceutical Applications

    SBC: Microtech Instruments, Inc.            Topic: 400

    ABSTRACT SUMMARY The outcome of this phase project will yield a turnkey system for spectroscopy polarimetry in the terahertz THz frequency range designed to support development of new drugs This system will directly probe protein vibrations using polarized terahertz radiation allowing researchers to rapidly characterize intramolecular vibrations which will help identify sites on ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Biocatalytic production of precursors to lutein and zeaxanthin to address age related macular degeneration

    SBC: EscaZyme Biochemicals, LLC            Topic: N

    Project Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostl ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Development of DR?1-MOG-35-55 for treatment of DR2 negative MS subjects

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: NIAID

    PROJECT SUMMARY ABSTRACT Our recently completed Phaseanimal studies demonstrated the ability of our novel second generation partialp MHC constructDRhMOGto treat acute and chronic EAE with potency comparable to the parent RTLmoleculepDRMOGin matched DRTg mice and in DRnegative mismatched miceHaving met our Phasemilestonesour Phase II application will produce a fully humanized DRhMOGmolecule and ass ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. DRα MOG A Novel Immunomodulatory Therapeutic for Stroke

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: 105

    This is a Phase I STTR to investigate the preclinical efficacy of a novel immunomodulator DR MOG in a clinically relevant thromboembolic stroke model in mice We have previously shown that T cells are activated after stroke infiltrate brain and exacerbate ischemic brain damage Strategies that reduce T cell activation and brain tissue infiltration have been investigated as potential therapeu ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Immersive Virtual Reality as a Tool to Improve Police Safety in Adolescents and Adults with ASD

    SBC: Floreo, Inc.            Topic: 103

    Floreo Technology proposes to develop the Police Safety Module PSM an innovative immersive mobile virtual reality VR application designed to train police safety in adolescents and adults with autism spectrum disorder ASD ASD has been increasing in prevalence over recent years While much attention has been paid to the causes and early diagnosis of ASD there remains a clear need for effec ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. A novel approach to treat non alcoholic steatohepatitis NASH

    SBC: MITOTHERAPEUTIX, LLC            Topic: 300

    Abstract The Specific Aim of this Phase I STTR proposal is to test the feasibility of treating non alcohol steatohepatitis NASH by increasing mitochondrial metabolism which is the main pathway for lipid catabolism in the liver NASH is a stage of non alcohol fatty liver disease NAFLD that has progressed to a pathological state NASH can lead to cirrhosis leading to liver failure or hepatocel ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma

    SBC: L2 DIAGNOSTICS LLC            Topic: 102

    DESCRIPTION provided by applicant Hepatocellular carcinoma HCC is the most prevalent cancer in human population and will lead to over deaths in the United States this year alone However the molecular mechanisms driving hepatocellular carcinoma HCC growth and metastasis remain elusive and there is a huge unmet medical need to find new therapeutic targets We performed an unbiased ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government